Introduction – What is Publication 5931?
IRS Publication 5931 is officially titled the “Pharmaceutical Industry Research Credit Audit Technique Guide” (Catalog Number 94696O). It serves as an instructional roadmap created by the Internal Revenue Service (IRS) Large Business and International (LB&I) division. Its primary goal is to guide revenue agents through the process of auditing research tax credit claims filed by life sciences and drug manufacturing companies.
While originally published with an April revision marker, IRS operational records confirmed through 2026 establish Publication 5931 as the governing audit framework for current examination cycles. Throughout 2026, the guide directly interacts with major procedural shifts, including mandatory project-level disclosures under Form 6765 Section G and updated accounting method rules issued for research and experimental expenses. Understanding this publication gives businesses a direct window into how IRS auditors evaluate scientific development.
Although an Audit Technique Guide is written for IRS field personnel, it is equally valuable for taxpayers. It outlines the legal boundaries of the Credit for Increasing Research Activities under Internal Revenue Code (IRC) Section 41. By reading this guide, companies can build transparent, compliant tax credit claims before an audit ever takes place.
Who Should Read This Publication
Publication 5931 is essential reading for anyone involved in the financial management or tax compliance of life sciences companies. This includes founders of early-stage biotech startups, chief financial officers (CFOs), and corporate controllers at commercial pharmaceutical firms.
Certified Public Accountants (CPAs), tax attorneys, and specialized R&D tax advisors should study this text closely. Because pharmaceutical research involves unique regulatory hurdles, standard tax advice often falls short without industry-specific context.
Independent research contractors and Clinical Research Organizations (CROs) can also benefit from reading it. Knowing how the IRS views contract research agreements helps service providers draft clearer contracts with their drug-sponsor clients.
Key Topics Covered
Publication 5931 bridges the gap between complex federal tax regulations and the daily operational reality of drug research. The IRS examines how companies develop new therapies from initial laboratory chemistry to commercial distribution.
The core subjects addressed in the guide include:
- The statutory Four-Part Test under Section 41 applied to pharmaceutical discovery.
- Categorization of drug development stages, from preclinical trials through post-market surveillance.
- Identification of “business components” for individual drug compounds and dosage formulations.
- Rules for qualifying employee wages, clinical testing supplies, and third-party contract research.
- Specific audit techniques, interviews, and document requests examiners use during an audit.
Detailed Breakdown of Main Concepts
The Four Stages of Drug Development
The IRS separates pharmaceutical development into distinct stages to evaluate whether activities qualify for tax credits. The first stage is Preclinical Discovery, where scientists test biological targets and chemical compounds. Activities in this stage generally meet the tax definition of qualified research because they resolve fundamental scientific uncertainties.
Stage Two covers Clinical Development, which includes Phase I, Phase II, and Phase III human clinical trials. These trials determine the safety, dosage, and efficacy of an investigational drug. Wages paid to clinical scientists and costs for trial supplies during this phase are frequently eligible for research credits.
Stage Three involves Regulatory Review with the Food and Drug Administration (FDA). Here, the IRS scrutinizes activities closely to separate scientific experimentation from purely clerical compliance. Stage Four covers Post-Marketing activities, such as Phase IV studies and routine commercial production, which generally do not qualify.
Qualified Research Activities (QRAs)
To qualify for the research credit, an activity must meet four statutory requirements known as the Four-Part Test. First, the expenditures must qualify as research expenses under tax code rules. Second, the work must be undertaken to discover information that is technological in nature.
Third, the taxpayer must intend to eliminate uncertainty regarding the capability, method, or design of a product. Fourth, substantially all of the activities must constitute a process of experimentation. In pharmaceutical research, lab trials, compound synthesis, and formal clinical studies typically satisfy these four prongs.
Qualified Research Expenses (QREs)
Only specific categories of expenses qualify for the research credit calculation. These include taxable wages paid to employees directly conducting, supervising, or supporting research. They also include consumable laboratory supplies, such as reagents, test chemicals, and lab animals used in testing.
Contract research expenses paid to outside clinical centers and laboratories also qualify, though usually at a statutory 65 percent rate. General overhead costs, building rent, capital equipment depreciation, and routine administrative salaries are strictly excluded.
| Development Category | IRS Treatment Under Pub 5931 | Primary Audit Focus |
|---|---|---|
| Preclinical Discovery | Generally Qualifies | Scientific notebooks and molecular target proof |
| Phase I–III Clinical Trials | Generally Qualifies | Trial protocols, patient safety logs, and CRO agreements |
| FDA Application Prep | Substantially Restricted | Separating clerical work from technical problem-solving |
| Phase IV / Commercial Scale | Generally Disallowed | Marketing focus vs. true scientific experimentation |
| Routine Quality Control | Disallowed | Verification of routine manufacturing standards |
Practical Examples or Scenarios
Scenario 1: The Phase II Clinical Study
A mid-sized biotech firm develops a new therapeutic molecule intended to treat rheumatoid arthritis. During the tax year, the company conducts a Phase II clinical trial to test drug efficacy across multiple dosage levels. The company incurs $1,200,000 in internal researcher wages, $300,000 in specialized test supplies, and pays $800,000 to an external trial management contractor.
Under Publication 5931, the IRS examiner will verify that the trial resolved technical uncertainties regarding proper dosage and safety. The internal wages and consumable test materials qualify fully. The contract research qualifies at the standard 65 percent rate ($520,000), yielding a strong, defensible pool of eligible research expenditures.
Scenario 2: Commercial Packaging and Routine Stability Testing
A pharmaceutical manufacturer receives FDA approval for an injectable medicine. In the following year, the packaging team alters the blister packs to improve shelf appeal and conducts routine batch stability testing required by regulatory standards. The company claims these expenses as qualified research.
Following the guidance in Publication 5931, the IRS auditor will disallow these claims. The packaging change was cosmetic rather than technical, meaning it lacked scientific uncertainty. Furthermore, post-approval batch testing represents routine quality control rather than experimental development.
How This Publication Relates to Specific Forms
Publication 5931 serves as the analytical guide behind IRS Form 6765, titled “Credit for Increasing Research Activities.” When filers calculate their credit on Form 6765, they must identify expenditures by specific business components. In 2026, with project-level reporting in Section G becoming mandatory for corporate returns, the granular guidelines in Publication 5931 dictate exactly how project data must be documented.
The publication also connects to Form 1120 (U.S. Corporation Income Tax Return) and Form 1120-S for S-corporations. Research credits directly reduce the final corporate income tax liability calculated on these primary forms. If a business files an amended return using Form 1120-X to claim a refund, IRS examiners use Publication 5931 to ensure the five essential refund claim items—including project descriptions and expense breakdowns—are present at the time of filing.
Finally, the guide intersects with Form 3115, used for changes in accounting methods. Because companies must amortize or expense research costs under IRC Section 174, Publication 5931 helps ensure the expenses claimed on Form 6765 match the accounting positions reported across company tax schedules.
Common Misunderstandings Clarified
A widespread misconception is that any scientific expenditure incurred by a pharmaceutical company automatically qualifies for the credit. In reality, the IRS explicitly draws a line between scientific business operations and eligible experimentation. Administrative oversight, marketing surveys, and regulatory filing assembly do not qualify simply because they happen in a medical company.
Another common mistake involves Phase IV post-marketing trials. Many businesses assume all clinical studies qualify. However, Publication 5931 notes that many Phase IV studies are conducted to promote brand awareness or expand market share rather than to test new scientific hypotheses. If a study lacks genuine technical uncertainty, the IRS will reject it.
Finally, taxpayers often believe that high-level payroll estimates and rough percentages are acceptable during an examination. The IRS strictly rejects arbitrary allocations. Examiners require contemporaneous records, such as time logs, lab reports, project codes, and formal meeting minutes, to connect employee wages directly to qualifying projects.
Why This Publication Matters for Taxpayers
Tax audits can be intimidating, costly, and time-consuming. Publication 5931 levels the playing field by revealing the precise questions, evaluation metrics, and checklists that IRS agents use in the field. When taxpayers know the rules in advance, they can design recordkeeping systems that meet audit expectations from day one.
Adhering to the principles in this guide also protects companies from costly penalties. Improperly claimed research credits can result in repayment demands, substantial interest, and accuracy-related penalties. Following the audit guide safeguards both your balance sheet and your credibility with tax authorities.
Frequently Asked Questions
Is IRS Publication 5931 legally binding like a statute?
No, an Audit Technique Guide is not formal tax law or official Treasury regulation. It represents the administrative position and examination instructions of the IRS. While courts and taxpayers cannot cite it as binding precedent, it reveals how IRS agents will evaluate your tax return.
Can early-stage biotech startups claim research credits using this guide?
Yes. Early-stage startups engaged in preclinical discovery or Phase I testing can claim research credits even if they have not yet generated revenue. Eligible qualified small businesses may also elect to apply research credits against employer payroll taxes instead of income taxes.
What records should a pharmaceutical company keep for an audit?
Companies should retain contemporaneous project records, including laboratory notebooks, FDA correspondence, trial protocols, and investigator agreements. They should also maintain detailed payroll records that separate direct research, technical supervision, and support tasks by project component.
Do payments to foreign research centers qualify under Publication 5931?
Generally, no. Federal tax law requires research activities to be conducted within the United States or its territories. Costs paid for clinical trials or laboratory testing conducted outside the country are non-qualifying research expenditures.
Conclusion
IRS Publication 5931 provides an indispensable blueprint for understanding pharmaceutical research tax credits. By detailing how revenue agents evaluate drug development stages, the guide removes guesswork from R&D tax compliance. Companies that align their recordkeeping with these audit standards can maximize their tax incentives while minimizing audit exposure.
As the IRS continues enforcing stricter project-level documentation rules throughout 2026, maintaining clear scientific and financial records is more critical than ever. Life sciences companies should consult with qualified tax professionals to review their R&D credit claims against the clear benchmarks set in Publication 5931.
